Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)- Insider Own51.56% Shs Outstand24.67M Perf Week-24.50%
Market Cap285.93M Forward P/E- EPS next Y- Insider Trans9.81% Shs Float11.95M Perf Month8.93%
Income- PEG- EPS next Q-0.69 Inst Own17.22% Short Float / Ratio0.38% / 0.26 Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Interest0.04M Perf Half Y-
Book/sh-5.82 P/B- EPS next Y- ROA- Target Price20.80 Perf Year-
Cash/sh1.85 P/C6.28 EPS next 5Y- ROE- 52W Range9.00 - 17.72 Perf YTD15.32%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-34.58% Beta-
Dividend %- Quick Ratio3.57 Sales past 5Y79.54% Gross Margin- 52W Low28.78% ATR1.46
Employees- Current Ratio3.57 Sales Q/Q- Oper. Margin- RSI (14)- Volatility15.10% 11.31%
OptionableNo Debt/Eq0.31 EPS Q/Q- Profit Margin- Rel Volume0.40 Prev Close13.00
ShortableYes LT Debt/Eq0.24 Earnings- Payout- Avg Volume175.18K Price11.59
Recom1.00 SMA20-4.43% SMA50-2.12% SMA200-2.12% Volume69,311 Change-10.85%
Date Action Analyst Rating Change Price Target Change
Nov-28-23Initiated Stifel Buy $20
Nov-28-23Initiated RBC Capital Mkts Outperform $22
Nov-28-23Initiated Leerink Partners Outperform $19
Nov-28-23Initiated JP Morgan Overweight $20
Nov-28-23Initiated Chardan Capital Markets Buy $23
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer's disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Longitude Capital Partners IV,10% OwnerNov 07Buy11.00454,5454,999,9952,567,100Nov 09 08:32 PM
Omega Fund VI, L.P.10% OwnerNov 07Buy11.00454,5454,999,9952,157,623Nov 09 08:36 PM
Lundbeckfond Invest A/S10% OwnerNov 07Buy11.00227,2722,499,9921,835,959Nov 09 08:33 PM